Even if the risk from immunosuppression can be eliminated, there is also the question of where cell therapy falls within the pipeline of standard of care treatments for poorly controlled diabetes, in the face of insulin therapy or insulin pumps which are less invasive. This evidence concerns the gene INS and diabetes mellitus.